Reaction

Oesophageal Stenosis reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 2,817 reports · 70 co-occurring drugs

As of the last recalculation, Oesophageal Stenosis appears in 2,817 FAERS reports alongside 70 co-occurring drug terms. The strongest observed disproportionality signal is PEGASPARGASE (PRR 13.4).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Pegaspargase	22	13.4	13.4
Sucralfate	38	11.9	11.9
Mycophenilic Acid	31	11.2	11.2
Alendronate Sodium	130	9.9	9.9
Cisplatin	97	9.5	9.5
Sucralfate Oral	18	9.4	9.4
Sucralfate Oral Suspension	18	9.4	9.4
Olmesartan Medoxomil	44	9.2	9.2
Valganciclovir Hydrochloride Powder,	14	8.5	8.5
Fluorouracil Cream, 0.5%	84	8.4	8.4
Fluorouracil	85	8.3	8.3
Mycophenolic Acid	35	8.2	8.2
Nystatin Ointment	27	7.7	7.7
Nystatin Cream	27	7.7	7.7
Valganciclovir	19	7.5	7.5
Valganciclovir Hydrochloride	19	7.5	7.5
Tolterodine Tartrate	9	7.4	7.4
Nystatin	27	7.4	7.4
Tacrolimus Ointment 0.1%	119	7.3	7.3
Tacrolimus Extended-Release Capsules	119	7.3	7.3
Promethazine Hydrochloride	18	7.2	7.2
Methocarbamol Tablets	16	7.1	7.1
Micafungin Sodium	8	7.0	7.0
Tacrolimus	141	6.9	7.0
Quinine	8	6.9	6.9
Methocarbamol	21	6.9	6.9
Hyoscyamine Sulfate	8	6.5	6.5
Tizanidine Hydrochloride	15	6.2	6.2
Teduglutide	11	6.1	6.1
Esomeprazole Magnesium	178	5.9	5.9
Mycophenolate Mofetil	103	5.8	5.8
Mycophenolate Mofetil Hydrochloride	103	5.8	5.8
Minocycline	9	5.7	5.7
Fulvestrant	24	5.4	5.4
Crizotinib	9	5.2	5.2
Raloxifene Hydrochloride	10	5.1	5.1
Melphalan Hydrochloride	16	4.7	4.7
Cefepime	9	4.7	4.7
Carboplatin	74	4.4	4.4
Capecitabine	52	4.3	4.3
Oxaliplatin	40	4.0	4.0
Nivolumab	51	4.0	4.0
Vincristine Sulfate	15	3.8	3.8
Paclitaxel (Aibumin-Bound)	41	3.7	3.7
Imatinib Mesylate	14	3.7	3.7
Pemetrexed Disodium	19	3.7	3.7
Docetaxel Anhydrous	33	3.6	3.7
Docetaxel	33	3.6	3.7
Dabrafenib	10	3.5	3.5
Irinotecan Hydrochloride	6	3.5	3.5
Alpelisib	4	3.4	3.4
Miconazole Nitrate	4	3.4	3.4
Palbociclib	43	3.4	3.4
Niraparib	10	3.3	3.3
Cetuximab	14	3.3	3.3
Paclitaxel	43	3.2	3.2
Pemetrexed	9	3.1	3.1
Erlotinib	4	3.1	3.1
Erlotinib Hydrochloride	5	3.0	3.0
Loratadine And Pseudoephedrine Sulfate	3	2.8	2.8
Fremanezumab-Vfrm	4	2.6	2.6
Ipilimumab	15	2.6	2.6
Durvalumab	7	2.5	2.5
Bosutinib	3	2.5	2.5
Lapatinib	5	2.4	2.4
Abemaciclib	6	2.2	2.2
Trifluridine And Tipiracil	3	2.1	2.1
Osimertinib	8	1.8	1.8
Bimekizumab	5	1.7	1.7
Palivizumab	3	1.4	1.4

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.